The Cuban Biotechnology and Pharmaceutical Industry Group (BioCubaFarma) has called on the global scientific community to attend the BioHabana 2022 International Congress, it was announced today.
According to a press release from the organisation, the event, scheduled to take place from 25 to 29 April, has as its main objective the translation of Life Sciences into Business Development, in a new context of science, innovation management and global health.
The meeting, which will take place at the Palacio de Convenciones in the capital of this Caribbean nation, will allow for a broad debate on the experiences and results of the participants, from both industrialised and developing countries, in order to build alliances that will have a greater impact on public health.
Cuba is a small country with scarce material resources and remarkable results in disease control, the BioCubaFarma communiqué stressed, while warning of the need to jointly address the increasing burden of mortality from chronic non-communicable diseases in the world in the future.
Among the main themes of the event will be the Covid-19 pandemic, medical technology and industry 4.0, as well as chronic inflammation, cancer and autoimmunity, agricultural biotechnology and brain diseases.
They will also address subjects such as bioprocesses and innovation in new business models for high-tech sectors.
The biological sciences, says the text, are going through a period of fundamental changes, similar to those that occurred in physics at the beginning of the 20th century, and the main driver of these changes is convergence with other sciences.
In this context, he says, the “global” nature of the challenges to human health (as illustrated by the Covid-19 pandemic), as well as the food, energy and environmental challenges, is increasingly evident.
He further notes that the pandemic response has demonstrated the responsiveness of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and inter-institutional approach that has achieved an unprecedented integration in the history of biomedical sciences.
“Now is the time to build on the momentum generated in the last two years to face the post-Covid-19 phase,” he stresses.